National Pension Service increased its position in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 6.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 375,973 shares of the medical research company’s stock after acquiring an additional 23,411 shares during the quarter. National Pension Service’s holdings in IQVIA were worth $72,646,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds also recently bought and sold shares of the company. California State Teachers Retirement System increased its holdings in shares of IQVIA by 18,735.4% during the 2nd quarter. California State Teachers Retirement System now owns 49,241,537 shares of the medical research company’s stock worth $9,514,450,000 after buying an additional 48,980,106 shares during the last quarter. BlackRock Inc. purchased a new stake in shares of IQVIA during the 2nd quarter valued at approximately $2,811,292,000. Boston Partners acquired a new position in IQVIA in the third quarter valued at approximately $676,698,000. Norges Bank purchased a new position in IQVIA in the fourth quarter worth approximately $497,445,000. Finally, Victory Capital Management Inc. grew its position in IQVIA by 2,628.1% in the fourth quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company’s stock worth $377,670,000 after acquiring an additional 1,614,063 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.
IQVIA Trading Up 1.9%
Shares of IQV stock opened at $262.09 on Friday. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $271.80. The company has a 50 day moving average price of $236.55 and a 200 day moving average price of $195.92. The stock has a market capitalization of $43.14 billion, a P/E ratio of 32.52, a price-to-earnings-growth ratio of 2.20 and a beta of 1.18. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71.
Insider Activity at IQVIA
In related news, insider Keriann Cherofsky sold 558 shares of the stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the transaction, the insider owned 2,989 shares of the company’s stock, valued at $732,932.69. This represents a 15.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Bhavik Patel sold 1,855 shares of the stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $235.27, for a total value of $436,425.85. Following the completion of the transaction, the insider owned 1,348 shares in the company, valued at approximately $317,143.96. The trade was a 57.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 15,581 shares of company stock worth $3,796,021 over the last quarter. 1.70% of the stock is currently owned by insiders.
Analysts Set New Price Targets
IQV has been the topic of a number of research analyst reports. Barclays restated an “overweight” rating on shares of IQVIA in a research report on Tuesday, July 28th. Robert W. Baird raised their price objective on IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. Mizuho boosted their price objective on shares of IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a report on Monday, July 13th. HSBC reaffirmed a “buy” rating and issued a $240.00 target price on shares of IQVIA in a research report on Monday, July 6th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $200.00 price target (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $243.62.
Get Our Latest Stock Report on IQV
About IQVIA
IQVIA Holdings Inc is a global provider of advanced analytics, technology solutions and contract research services for the life sciences industry. The company supports pharmaceutical, biotechnology and medical device companies throughout the product life cycle, from research and clinical development through commercialization and post-market activities.
Its offerings include clinical trial management, site and patient services, real-world evidence, healthcare data, regulatory and safety services, commercial analytics, consulting, and technology platforms.
Read More
- Five stocks we like better than IQVIA
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
